Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Arkansas for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Arkansas only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Arkansas (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Sue Tsuda (NPI 1275532715)

Field	Value
Entity Type	Individual
Organization	Sue Tsuda
Address	350 Salem Rd Ste 4
City	Conway
State	AR
ZIP	72034
Taxonomy	Medical Oncology Physician
NPI Enumerated	July 18, 2005

Payer Source	Total Paid
Medicare	$3.1M
Medicaid	$0

Key Findings

This provider’s Medicare billing profile is dominated by oncology biologic and immunotherapy administration. The top three revenue drivers are J9271 ($1.4M, 46.2%), J9299 ($749.3K, 24.5%), and Q5118 ($154.6K, 5.1%), and the overall Medicare total is $3.1M, indicating the practice is primarily structured around infused cancer therapies rather than procedural surgery or primary care visits. Supplemental chemotherapy administration codes such as 96413 ($68.6K, 2.2%) and infusion/start codes like 96365 ($19.4K, 0.6%) further support a specialty infusion practice model.

Revenue concentration is high: the precomputed top-3 codes account for 75.7% of this provider’s total Medicare revenue. That concentration — with nearly three quarters of Medicare revenue coming from two checkpoint inhibitors and one bevacizumab biosimilar — suggests the practice’s topline is highly dependent on continued prescribing and reimbursement for these specific immunotherapies and biosimilars.

The provider is effectively single-payer in scope: Medicare accounts for the entire recorded public-payer footprint ($3.1M) while there is no Medicaid billing on file. The absence of Medicaid volume means payer-mix exposure and growth opportunities will be driven largely by Medicare demand and commercial contracts rather than state Medicaid programs.

Competitive standing on key oncology agents is strong nationally. J9271 ranks #78 of 1841 providers nationally (96th percentile; notably above typical national volume for this code) with 33.6K claims and an average paid/claim of $42, and J9299 ranks #70 of 505 providers nationally (86th percentile) with 31.2K claims and an average paid/claim of $24, while Q5118 ranks #8 of 161 providers nationally (96th percentile; notably above typical national volume for this code). Q5118’s top-10 national rank indicates particular prominence among biosimilar users, and the high ranks for the two checkpoint inhibitors mark this provider as a major chemotherapy/immunotherapy administrator relative to peers.

Several administration and supportive medication codes are statistical outliers or notably elevated, reflecting a high-throughput infusion operation. Codes with high percentile standing include 96413 (98th percentile; notably above typical national volume), Q5106 (rank #16 of 695; 98th percentile; notably above typical national volume), and 96375 (98th percentile; notably above typical national volume), indicating above-typical volumes for chemotherapy delivery and supportive agent use compared with national peers.

E/M coding indicates substantial complexity and follow-up care consistent with oncology management. The provider reports 99215 activity (620 claims, $77.5K, 2.5%) and that code ranks #1109 of 145531 providers nationally (99th percentile; extreme outlier, far above typical national volume), while 99214 also contributes materially (908 claims, $75.4K, 2.5%) — together these suggest frequent high-complexity office encounters and ongoing management of complex patients.

The NPI tenure (enumerated 2005-07-18, ~21 years ago) shows long-standing enrollment, which aligns with the sustained high volumes reported across infusion and E/M codes. Long tenure combined with concentrated oncology billing patterns implies an established specialty practice with operational systems to support high-volume biologic administration and follow-up care.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

55 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	33,600	$40	$1.4M
J9299	Injection, nivolumab, 1 mg	31,220	$20	$749.3K
Q5118	Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg	6,440	$20	$154.6K
J1437	Injection, ferric derisomaltose, 10 mg	8,100	$20	$137.7K
J0897	Injection, denosumab, 1 mg	6,480	$20	$116.6K
99215	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the…	620	$130	$77.5K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	910	$80	$75.4K
Q5106	Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units	11,860	$10	$71.2K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	790	$90	$68.6K
85025	A complete blood count (better known as a CBC) is a blood test request by a doctor that provides detailed information about various types of cells in a patient's blood. Usually a pathologist or a…	4,150	$10	$33.2K

Showing 1–10 of 55

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 55 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Arkansas Distribution

Sue Tsuda — 8 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Arkansas

Full comparison — all codes billed, vs. state median

55 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	4	40	20,700	$40	$896.3K
J9299	4	30	15,660	$20	$432.9K
J1437	10	20	6,450	$20	$107.8K
J0897	40	160	2,580	$20	$89.7K
Q5118	1	10	2,110	$20	$64.3K
J0885	39	40	4,070	$10	$38K
96413	13	80	380	$90	$36.6K
Q5106	1	10	2,410	$10	$19.2K
99214	233	4,300	130	$70	$18.8K
99232	1,020	1,450	130	$60	$14.7K

Showing 1–10 of 55

Related Providers

Other providers that share a Tax Identification Number (TIN) with Sue Tsuda, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Columbus Radiology Corp	OH	Diagnostic Radiology Physician	$0	$49.9M
Wilfredo Blasini	FL	Clinical Pathology Physician	$16.9M	$307.9K
Ryan Olson	FL	Anatomic Pathology & Clinical Pathology Physician	$12.8M	$80
American Oncology Partners PA	OH	Hematology & Oncology Physician	$0	$11.8M
Robert Mcdonald	AZ	Diagnostic Radiology Physician	$7.5M	$0
David Smith	MD	Hematology & Oncology Physician	$6.4M	$0
Stephen Divers	AR	Hematology & Oncology Physician	$3.9M	$1.5K
Robert Muldoon	AR	Hematology & Oncology Physician	$3.2M	$0
Bradley Sumrall	GA	Medical Oncology Physician	$3.1M	$0
Linda Hendricks	GA	Specialist	$3.1M	$0

Nearby Providers

Other providers in the same ZIP code as Sue Tsuda, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Kid Success, Inc.	AR	Rehabilitation Clinic/Center	$0	$140.9M
Milestones Services, Inc.	AR	Developmentally Disabled Services Day Training Agency	$0	$11.6M
Conway Regional Medical Center Inc	AR	General Acute Care Hospital	$0	$10.6M
Independent Living Services, Inc.	AR	Developmentally Disabled Services Day Training Agency	$0	$9.8M
Counseling Associates, Inc	AR	Mental Health Clinic/Center (Including Community Mental Health Center)	$0	$9.6M
Pediatrics Plus Therapy Services, LLC	AR	Developmental Disabilities Clinic/Center	$0	$7.1M
Central Arkansas Pediatrics, P.A.	AR	Pediatrics Physician	$0	$6.7M
Aaron K. Forrester Dds, PLLC	AR	Pediatric Dentistry	$0	$5.7M
Conway Childrens Clinic PA Corp	AR	Pediatrics Physician	$0	$4.8M
Arkansas Pediatrics Of Conway, PA	AR	Pediatrics Physician	$0	$3.9M

Sue Tsuda — Billing Profile & Reimbursement Data

Sign up for Sue Tsuda — Billing Profile & Reimbursement Data policy alerts

Sue Tsuda — Billing Profile & Reimbursement Data

Sign up for Sue Tsuda — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References